glp-1 obesity drug news october 21 2025 today Unpacking $100B+ Obesity Market Opportunity: What It Means for Biopharma, Payers, and Providers GLP-1 Market Industry Trends and

: Keep out of sight and reach of children

In a 12-week randomized clinical trial involving 300 obese adults, participants receiving 1 mg daily of AOD-9604 lost an average of 2.6 kg (approximately 5.7 pounds) compared to 0.8 kg (1.8 pounds) in the placebo group

References 1.Mueller SG

A priori , this positions those neurons as potential contributors to the neural circuits controlling energy expenditure by regulating BAT thermogenesis in rodents

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved these agents for glycaemic control in type 2 diabetes and, in specific formulations and doses (semaglutide as Wegovy and liraglutide as Saxenda), for weight management in adults with obesity or overweight with weight-related comorbidities